<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1473" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1473/" /><meta name="ncbi_pagename" content="OPA3-Related 3-Methylglutaconic Aciduria - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>OPA3-Related 3-Methylglutaconic Aciduria - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="OPA3-Related 3-Methylglutaconic Aciduria" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2013/12/19" /><meta name="citation_author" content="Meral Gunay-Aygun" /><meta name="citation_author" content="Marjan Huizing" /><meta name="citation_author" content="Yair Anikster" /><meta name="citation_pmid" content="20301646" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1473/" /><meta name="citation_keywords" content="3-Methylglutaconic Aciduria Type 3" /><meta name="citation_keywords" content="Costeff Optic Atrophy Syndrome" /><meta name="citation_keywords" content="Costeff Syndrome" /><meta name="citation_keywords" content="Optic Atrophy Plus Syndrome" /><meta name="citation_keywords" content="Costeff Syndrome" /><meta name="citation_keywords" content="Optic Atrophy Plus Syndrome" /><meta name="citation_keywords" content="Costeff Optic Atrophy Syndrome" /><meta name="citation_keywords" content="3-Methylglutaconic Aciduria Type 3" /><meta name="citation_keywords" content="Optic atrophy 3 protein" /><meta name="citation_keywords" content="OPA3" /><meta name="citation_keywords" content="OPA3-Related 3-Methylglutaconic Aciduria" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="OPA3-Related 3-Methylglutaconic Aciduria" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Meral Gunay-Aygun" /><meta name="DC.Contributor" content="Marjan Huizing" /><meta name="DC.Contributor" content="Yair Anikster" /><meta name="DC.Date" content="2013/12/19" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1473/" /><meta name="description" content="OPA3-related 3-methylglutaconic aciduria is characterized by optic atrophy and/or choreoathetoid movement disorder with onset before age ten years. Optic atrophy is associated with progressive, decreased visual acuity within the first years of life, sometimes associated with infantile-onset horizontal nystagmus. Most individuals have chorea, often severe enough to restrict ambulation. Some are confined to a wheelchair from an early age. Although most individuals develop spastic paraparesis, mild ataxia, and occasional mild cognitive deficit in their second decade, the course of the disease is relatively stable." /><meta name="og:title" content="OPA3-Related 3-Methylglutaconic Aciduria" /><meta name="og:type" content="book" /><meta name="og:description" content="OPA3-related 3-methylglutaconic aciduria is characterized by optic atrophy and/or choreoathetoid movement disorder with onset before age ten years. Optic atrophy is associated with progressive, decreased visual acuity within the first years of life, sometimes associated with infantile-onset horizontal nystagmus. Most individuals have chorea, often severe enough to restrict ambulation. Some are confined to a wheelchair from an early age. Although most individuals develop spastic paraparesis, mild ataxia, and occasional mild cognitive deficit in their second decade, the course of the disease is relatively stable." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1473/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/mga3/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1473/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE885619E03EEB71000000000B1003AC.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1473_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1473_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/leigh-nucl-ov/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/dfnb9/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1473_"><span class="title" itemprop="name"><i>OPA3</i>-Related 3-Methylglutaconic Aciduria</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: 3-Methylglutaconic Aciduria Type 3, Costeff Optic Atrophy Syndrome, Costeff Syndrome, Optic Atrophy Plus Syndrome</div><p class="contrib-group"><span itemprop="author">Meral Gunay-Aygun</span>, MD, <span itemprop="author">Marjan Huizing</span>, PhD, and <span itemprop="author">Yair Anikster</span>, MD, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1473_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1473_ai__"><div class="contrib half_rhythm"><span itemprop="author">Meral Gunay-Aygun</span>, MD<div class="affiliation small">National Human Genome Research Institute<br />Medical Genetics Branch<br />Section on Human Biochemical Genetics<br />National Institutes of Health<br />Bethesda, Maryland</div><div class="affiliation small">Associate Professor of Pediatrics and Genetics, Institute of Genetic Medicine<br />Departments of Pediatrics and Genetics<br />Johns Hopkins University School of Medicine<br />Baltimore, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@nugyagm" class="oemail">vog.hin.liam@nugyagm</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Marjan Huizing</span>, PhD<div class="affiliation small">National Human Genome Research Institute<br />Medical Genetics Branch<br />Section on Human Biochemical Genetics<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@gniziuhm" class="oemail">vog.hin.liam@gniziuhm</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Yair Anikster</span>, MD, PhD<div class="affiliation small">Head of Metabolic Unit, Safra Children's Hospital<br />Sheba Medical Center<br />Tel Hashomer, Israel<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="li.vog.htlaeh.abehs@retskina.riay" class="oemail">li.vog.htlaeh.abehs@retskina.riay</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 28, 2006</span>; Last Update: <span itemprop="dateModified">December 19, 2013</span>.</p><p><em>Estimated reading time: 16 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="mga3.Summary" itemprop="description"><h2 id="_mga3_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>OPA3</i>-related 3-methylglutaconic aciduria is characterized by optic atrophy and/or choreoathetoid movement disorder with onset before age ten years. Optic atrophy is associated with progressive, decreased visual acuity within the first years of life, sometimes associated with infantile-onset horizontal nystagmus. Most individuals have chorea, often severe enough to restrict ambulation. Some are confined to a wheelchair from an early age. Although most individuals develop spastic paraparesis, mild ataxia, and occasional mild cognitive deficit in their second decade, the course of the disease is relatively stable.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of <i>OPA3</i>-related 3-methylglutaconic aciduria is suggested by elevated urinary excretion of 3-methylglutaconate (3-MGC) and 3-methylglutaric acid (3-MGA) and confirmed by identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>OPA3</i> pathogenic variants.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Supportive and often provided by a multidisciplinary team; treatment of visual impairment, spasticity, and movement disorder as in the general population.</p><p><i>Agents/circumstances to avoid:</i> Use of tobacco, alcohol, and medications known to impair mitochondrial function.</p></div><div><h4 class="inline">Genetic counseling.</h4><p><i>OPA3</i>-related 3-methylglutaconic aciduria is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> for pregnancies at increased risk are possible if both pathogenic variants have been identified in an affected family member.</p></div></div><div id="mga3.Diagnosis"><h2 id="_mga3_Diagnosis_">Diagnosis</h2><p><b>The diagnosis of <i>OPA3</i>-related 3-methylglutaconic aciduria is suspected</b> in a child with relatively normal early development and growth in combination with the following:</p><ul><li class="half_rhythm"><div>Bilateral early-onset optic atrophy</div></li><li class="half_rhythm"><div>Choreoathetoid movement disorder</div></li></ul><p>Note: Progressive spasticity, cerebellar ataxia, and cognitive deterioration are variably seen in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children and more commonly at later stages.</p><p><b>The diagnosis is confirmed</b> by documentation of:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Increased urinary excretion of (3-MGC) and 3-methylglutaric acid (3-MGA).</b> 3-MGC and 3-MGA are measured in the urine using gas chromatography-mass spectrometry (GC-MS). In <i>OPA3</i>-related 3-methylglutaconic aciduria, urinary 3-MGC and 3-MGA are mildly increased (combined elevation &#x0003c;200 mmol/mol creatinine) (<a class="figpopup" href="/books/NBK1473/table/mga3.T.combined_urinary_excretion_of_3mg/?report=objectonly" target="object" rid-figpopup="figmga3Tcombinedurinaryexcretionof3mg" rid-ob="figobmga3Tcombinedurinaryexcretionof3mg">Table 1</a>).</div><div class="half_rhythm">Note: (1) 3-MGA is derived from hydrogenation of 3-methylglutaconyl-CoA. (2) Individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria have normal laboratory values for the following:</div><ul><li class="half_rhythm"><div>Serum bicarbonate concentration</div></li><li class="half_rhythm"><div>Liver and kidney function tests</div></li><li class="half_rhythm"><div>Serum and cerebrospinal fluid (CSF) lactic acid concentrations</div></li><li class="half_rhythm"><div>Serum creatinine phosphokinase (CK) activity</div></li></ul></li></ul><div id="mga3.T.combined_urinary_excretion_of_3mg" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Combined Urinary Excretion of 3-MGC and 3-MGA in <i>OPA3</i>-Related 3-Methylglutaconic Aciduria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1473/table/mga3.T.combined_urinary_excretion_of_3mg/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mga3.T.combined_urinary_excretion_of_3mg_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Combined Urinary Excretion: Range</th></tr><tr><th headers="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2" id="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">In mmol/mol Creatinine</th><th headers="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2" id="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">In &#x000b5;mol/L</th></tr></thead><tbody><tr><td headers="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria</td><td headers="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2 hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9-187</td><td headers="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2 hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">141-2245</td></tr><tr><td headers="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal controls</td><td headers="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2 hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.2-7</td><td headers="hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_1_2 hd_h_mga3.T.combined_urinary_excretion_of_3mg_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20-98</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">In a study of 39 individuals</p></div></dd></dl></div></div></div><ul><li class="half_rhythm"><div><b>Biallelic pathogenic variants in <i>OPA3</i></b></div><ul><li class="half_rhythm"><div>If clinical findings point to <i>OPA3</i>-related 3-methylglutaconic aciduria and urinary excretion of 3-MGC and 3-MGA is elevated, the diagnosis can be confirmed by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>OPA3</i>.</div></li><li class="half_rhythm"><div>Because the excretion of 3-MGC and 3-MGA is variable among individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria (sometimes even overlapping that of normal controls) and is not always easy to detect on urine organic acid analysis, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> should be used in individuals whose findings otherwise strongly suggest <i>OPA3</i>-related 3-methylglutaconic aciduria.</div></li><li class="half_rhythm"><div>To date, the <a class="figpopup" href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object" rid-figpopup="figmga3Tselectedopa3variants" rid-ob="figobmga3Tselectedopa3variants">c.143-1G&#x0003e;C</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals of Iraqi Jewish descent. Thus, targeted analysis for the <a class="figpopup" href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object" rid-figpopup="figmga3Tselectedopa3variants" rid-ob="figobmga3Tselectedopa3variants">c.143-1G&#x0003e;C</a> pathogenic variant should be performed first in affected individuals of Iraqi Jewish origin.</div></li></ul></li></ul><div id="mga3.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>OPA3</i>-Related 3-Methylglutaconic Aciduria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1473/table/mga3.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mga3.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant Detectable by Method</th></tr><tr><th headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Iraqi Jewish</th><th headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Non-Iraqi Jewish</th></tr></thead><tbody><tr><td headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>OPA3</i></td><td headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants&#x000a0;<sup>2</sup></td><td headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 3</td><td headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">See footnote 4</td></tr><tr><td headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>5</sup></td><td headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Deletion/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> analysis&#x000a0;<sup>6</sup></td><td headers="hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_mga3.T.molecular_genetic_testing_used_in_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mga3.TF.2.1"><p class="no_margin">See <a href="/books/NBK1473/#mga3.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein. See <a href="#mga3.Resources">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>2. </dt><dd><div id="mga3.TF.2.2"><p class="no_margin">Variant panels may vary by laboratory.</p></div></dd><dt>3. </dt><dd><div id="mga3.TF.2.3"><p class="no_margin">The variant <a class="figpopup" href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object" rid-figpopup="figmga3Tselectedopa3variants" rid-ob="figobmga3Tselectedopa3variants">c.143-1G&#x0003e;C</a> accounts for 100% of pathogenic variants in the Iraqi Jewish population [<a class="bk_pop" href="#mga3.REF.anikster.2001.1218">Anikster et al 2001</a>].</p></div></dd><dt>4. </dt><dd><div id="mga3.TF.2.4"><p class="no_margin">The variant <a class="figpopup" href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object" rid-figpopup="figmga3Tselectedopa3variants" rid-ob="figobmga3Tselectedopa3variants">c.320_337del</a>, found in an individual of Turkish-Kurdish origin with <i>OPA3</i>-related 3-methylglutaconic aciduria, is the first <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found to date in an individual of non-Iraqi Jewish origin [<a class="bk_pop" href="#mga3.REF.kleta.2002.201">Kleta et al 2002</a>]. The <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variant <a class="figpopup" href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object" rid-figpopup="figmga3Tselectedopa3variants" rid-ob="figobmga3Tselectedopa3variants">c. 415C&#x0003e;T</a> (p.Gln139Ter), found in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state in an individual of Indian origin with <i>OPA3</i>-related 3-methylglutaconic aciduria, is the second pathogenic variant found to date in an individual of non-Iraqi Jewish origin [<a class="bk_pop" href="#mga3.REF.ho.2008.s419">Ho et al 2008</a>].</p></div></dd><dt>5. </dt><dd><div id="mga3.TF.2.5"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>6. </dt><dd><div id="mga3.TF.2.6"><p class="no_margin">Testing that identifies <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications not detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of the coding and flanking <a class="def" href="/books/n/gene/glossary/def-item/intronic/">intronic</a> regions of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and <a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> (CMA) that includes this gene/<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> segment.</p></div></dd><dt>7. </dt><dd><div id="mga3.TF.2.7"><p class="no_margin">To date, no deletions or duplications involving <i>OPA3</i> have been reported to cause <i>OPA3</i>-related 3-methylglutaconic aciduria; however, a systematic analysis has yet to be performed.</p></div></dd></dl></div></div></div></div><div id="mga3.Clinical_Characeristics"><h2 id="_mga3_Clinical_Characeristics_">Clinical Characeristics</h2><div id="mga3.Clinical_Description"><h3>Clinical Description</h3><p>Most individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria present within the first ten years of life with decreased visual acuity and/or choreoathetoid movement disorder. Although most develop spastic paraparesis, mild ataxia, and occasional mild cognitive deficit in their second decade, the course of the disease is relatively stable.</p><p><b>Optic atrophy</b> manifests as decreased visual acuity within the first years of life, sometimes associated with infantile-onset horizontal nystagmus. The optic discs are pathologically pale, and the papillary vasculature is attenuated. Visual evoked potentials reveal bilateral prolonged latencies consistent with optic atrophy.</p><p>In 36 individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria, visual acuity decreased with age:</p><ul><li class="half_rhythm"><div>In two children age two years, visual acuity appeared to be normal.</div></li><li class="half_rhythm"><div>In 14 individuals age three to 21 years (14.2&#x000b1;5.5), visual acuity was 6/21 or less.</div></li><li class="half_rhythm"><div>In 20 individuals age five to 37 years (18&#x000b1;9.5), visual acuity was 3/60 or less.</div></li></ul><p>Some children have strabismus and gaze apraxia.</p><p>The electroretinogram (ERG) is normal.</p><p><b>Extrapyramidal dysfunction and spasticity</b> cause most of the observed motor disability.</p><p>Most individuals have chorea, often severe enough to restrict ambulation. Some are confined to a wheelchair from an early age. In 36 individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria, extrapyramidal signs:</p><ul><li class="half_rhythm"><div>Caused major disability in 17 individuals age two to 37 years (mean 16.1&#x000b1;17.8)</div></li><li class="half_rhythm"><div>Caused minor disability in maintaining stable posture and fine motor activities in 12 individuals age two to 26 years (11.7&#x000b1;8.1)</div></li><li class="half_rhythm"><div>Caused mild symptoms with no resulting disability in three individuals age 15 to 36 years</div></li><li class="half_rhythm"><div>Were absent in four individuals ages 13 to 32 years</div></li></ul><p>Unstable spastic gait, increased tendon reflexes, and positive Babinski sign may be seen. In 36 individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria, spasticity was age-related:</p><ul><li class="half_rhythm"><div>Nine individuals age two to 12 years (5.9&#x000b1;3.5) did not have spasticity.</div></li><li class="half_rhythm"><div>Four individuals age 11 to 26 years had mild spasticity but no related disability.</div></li><li class="half_rhythm"><div>Eleven individuals age 13 to 37 years (21.4&#x000b1;9.3) had mild spasticity-related disability.</div></li><li class="half_rhythm"><div>Twelve individuals age nine to 26 years (17.0&#x000b1;4.8) had severe spasticity-related disability.</div></li></ul><p><b>Cerebellar dysfunction</b> is usually mild. Ataxia and dysarthria causing mostly mild disability were detected in 18 of the 36 individuals reported by <a class="bk_pop" href="#mga3.REF.elpeleg.1994.167">Elpeleg et al [1994]</a>.</p><p><b>Cognitive impairment</b> is seen in some individuals. Of 36 individuals:</p><ul><li class="half_rhythm"><div>Nineteen individuals age two to 36 years (16.&#x000b1;18.7) had an IQ of &#x02265;71.</div></li><li class="half_rhythm"><div>Thirteen individuals age two to 37 years (14.7&#x000b1;9.2) had an IQ between 55 and 71.</div></li><li class="half_rhythm"><div>Four individuals age nine to 26 years had an IQ between 40 and 54</div></li></ul><p><b>Other</b></p><ul><li class="half_rhythm"><div>Affected adults in the fourth decade of life have been reported; life expectancy beyond the fourth decade is unknown.</div></li><li class="half_rhythm"><div>Cranial nerve functions, sensation, and muscle tone are normal.</div></li><li class="half_rhythm"><div>Seizures are not typical in <i>OPA3</i>-related 3-methylglutaconic aciduria. Partial seizures were reported in one individual.</div></li><li class="half_rhythm"><div>Individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria have no cardiac or structural brain abnormalities.</div></li><li class="half_rhythm"><div>The level of 3-methylglutaconate (3-MGC) or 3-methylglutaric acid (3-MGA) in urine does not correlate with the degree of neurologic damage.</div></li></ul></div><div id="mga3.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>The limited number of pathogenic variants found to date does not permit <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a>.</p><p>All individuals of Iraqi Jewish origin with <i>OPA3</i>-related 3-methylglutaconic aciduria have the same <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>; however, the phenotypic severity varies, even within the same family.</p></div><div id="mga3.Prevalence"><h3>Prevalence</h3><p><i>OPA3</i>-related 3-methylglutaconic aciduria has been reported in approximately 40 individuals of Iraqi Jewish origin [<a class="bk_pop" href="#mga3.REF.anikster.2001.1218">Anikster et al 2001</a>] and in one individual of Kurdish-Turkish descent [<a class="bk_pop" href="#mga3.REF.kleta.2002.201">Kleta et al 2002</a>].</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/carrier-rate/">carrier rate</a> in Iraqi Jews is estimated to be 1:10 [<a class="bk_pop" href="#mga3.REF.anikster.2001.1218">Anikster et al 2001</a>].</p></div></div><div id="mga3.Genetically_Related_Allelic_Disorde"><h2 id="_mga3_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p>Two <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>OPA3</i> pathogenic variants, <a class="figpopup" href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object" rid-figpopup="figmga3Tselectedopa3variants" rid-ob="figobmga3Tselectedopa3variants">p.Gly93Ser</a> and <a class="figpopup" href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object" rid-figpopup="figmga3Tselectedopa3variants" rid-ob="figobmga3Tselectedopa3variants">p.Gln105Glu</a>, were reported in two families with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy and cataract [<a class="bk_pop" href="#mga3.REF.reynier.2004.e110">Reynier et al 2004</a>].</p></div><div id="mga3.Differential_Diagnosis"><h2 id="_mga3_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Disorders in which excretion of 3-methylglutaconate (3-MGC) is increased</b></p><p>Increased urinary excretion of the branched-chain organic acid 3-methylglutaconate (3-MGC) is a relatively common finding in children investigated for suspected inborn errors of metabolism [<a class="bk_pop" href="#mga3.REF.gunayaygun.2005.1">Gunay-Aygun 2005</a>]. 3-MGC is an intermediate of leucine degradation and the mevalonate shunt pathway that links sterol synthesis with mitochondrial acetyl-CoA metabolism (<a class="figpopup" href="/books/NBK1473/figure/mga3.F1/?report=objectonly" target="object" rid-figpopup="figmga3F1" rid-ob="figobmga3F1">Figure 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figmga3F1" co-legend-rid="figlgndmga3F1"><a href="/books/NBK1473/figure/mga3.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figmga3F1" rid-ob="figobmga3F1"><img class="small-thumb" src="/books/NBK1473/bin/mga3-Image001.gif" src-large="/books/NBK1473/bin/mga3-Image001.jpg" alt="Figure 1. " /></a><div class="icnblk_cntnt" id="figlgndmga3F1"><h4 id="mga3.F1"><a href="/books/NBK1473/figure/mga3.F1/?report=objectonly" target="object" rid-ob="figobmga3F1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Metabolic pathway diagram showing branched-chain organic acid 3-MGC as an intermediate of leucine degradation and the mevalonate shunt pathway that links sterol synthesis with mitochondrial acetyl-CoA </p></div></div><p>Classification of inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature has recently been updated by <a class="bk_pop" href="#mga3.REF.wortmann.2013a.923">Wortmann et al [2013a]</a> and <a class="bk_pop" href="#mga3.REF.wortmann.2013b.913">Wortmann et al [2013b]</a> (<a class="figpopup" href="/books/NBK1473/table/mga3.T.new_classification_for_inborn_err/?report=objectonly" target="object" rid-figpopup="figmga3Tnewclassificationforinbornerr" rid-ob="figobmga3Tnewclassificationforinbornerr">Table 3</a>). Clinical features (<a class="figpopup" href="/books/NBK1473/table/mga3.T.new_classification_for_inborn_err/?report=objectonly" target="object" rid-figpopup="figmga3Tnewclassificationforinbornerr" rid-ob="figobmga3Tnewclassificationforinbornerr">Table 3</a>) and biochemical findings (<a class="figpopup" href="/books/NBK1473/table/mga3.T.urinary_excretion_of_3mgc_and_3mg/?report=objectonly" target="object" rid-figpopup="figmga3Turinaryexcretionof3mgcand3mg" rid-ob="figobmga3Turinaryexcretionof3mgcand3mg">Table 4</a>) of the 3-MGCA syndromes vary. Tissues with higher requirements for oxidative metabolism, such as the central nervous system and cardiac and skeletal muscle, are predominantly affected.</p><p>To explore whether pathogenic variants in <i>OPA3</i> are present in individuals with nonspecific neurologic abnormalities and unexplained 3-MGCA, 11 individuals were screened; none were found to have pathogenic variants, suggesting that mutation of <i>OPA3</i> is not a common cause of 3-MGCA in the absence of typical clinical features of <i>OPA3</i>-related 3-methylglutaconic aciduria [<a class="bk_pop" href="#mga3.REF.neas.2005.525">Neas et al 2005</a>].</p><p>Five forms of 3-methylglutaconic aciduria (3-MGCA) have been recognized (<a class="figpopup" href="/books/NBK1473/table/mga3.T.new_classification_for_inborn_err/?report=objectonly" target="object" rid-figpopup="figmga3Tnewclassificationforinbornerr" rid-ob="figobmga3Tnewclassificationforinbornerr">Table 3</a>) [<a class="bk_pop" href="#mga3.REF.sweetman.2001">Sweetman &#x00026; Williams 2001</a>, <a class="bk_pop" href="#mga3.REF.gunayaygun.2005.1">Gunay-Aygun 2005</a>, <a class="bk_pop" href="#mga3.REF.wortmann.2013a.923">Wortmann et al 2013a</a>, <a class="bk_pop" href="#mga3.REF.wortmann.2013b.913">Wortmann et al 2013b</a>]. The exact source of 3-MGC is known in only 3-methylglutaconyl-CoA hydratase deficiency, the rarest of the five types, caused by primary deficiency of the mitochondrial enzyme 3-methylglutaconyl-CoA hydratase (3-MGCH), resulting in a block of leucine degradation.</p><div id="mga3.T.new_classification_for_inborn_err" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>New Classification for Inborn Errors of Metabolism with 3-Methylglutaconic Aciduria as Discriminative Feature</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1473/table/mga3.T.new_classification_for_inborn_err/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mga3.T.new_classification_for_inborn_err_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Patho-Mechanism</th><th id="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disease Name</th><th id="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Former Designation</th><th id="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Additional Hallmarks&#x000a0;<sup>1</sup> of Phenotype</th><th id="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th></tr></thead><tbody><tr><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_1 hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2 hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3 hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4 hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Primary 3-MGA-uria</b></td></tr><tr><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Organic aciduria</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-methylglutaconyl-CoA hydratase deficiency (<i>AUH</i> defect)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-MGCA type I<br />(3-MGCA-1)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Adult onset leukoencephalopathy, dementia, progressive spasticity</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_1 hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2 hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3 hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4 hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" colspan="5" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><b>Secondary 3-MGA-uria</b></td></tr><tr><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Defective phospholipid remodeling</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TAZ</i> defect (<a href="/books/n/gene/barth/">Barth syndrome</a>)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-MGCA type II<br />(3-MGCA-2)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">(Cardio)myopathy, short stature, neutropenia, hypocholesterolemia, cognitive <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, mild <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features, OXPHOS dysfunction</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">XL</td></tr><tr><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>SERAC1</i> defect (<a href="/books/n/gene/megdel/">MEGDEL syndrome</a>)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-MGCA type IV<br />(3-MGCA-4)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Progressive spasticity, dystonia, deafness, Leigh syndrome-like MRI, severe psychomotor retardation, hypocholesterolemia, OXPHOS dysfunction</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Mitochondrial membrane disorder</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>OPA3</i> defect (Costeff syndrome)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-MGCA type III<br />(3-MGCA-3)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ataxia/extrapyramidal dysfunction, optic atrophy</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>TMEM70</i> defect</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-MGCA type IV<br />(3-MGCA-4)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Broad <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, hypertrophic cardiomyopathy, myopathy, <a class="def" href="/books/n/gene/glossary/def-item/dysmorphic/">dysmorphic</a> features, cataracts, psychomotor retardation, ATPase deficiency, lactic acidosis, hyperammonemia</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>DNAJC19</i> defect (DCMA syndrome)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-MGCA type V<br />(3-MGCA-5)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dilated cardiomyopathy, ECG abnormalities, non-progressive cerebellar ataxia, Ssmall atrophic testes, cryptorchidism, growth failure, anemia, steatosis hepatitis</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NOS 3-MGA-uria</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-MGCA type IV<br />(3-MGCA-4)</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variable, mostly progressive neurologic disease</td><td headers="hd_h_mga3.T.new_classification_for_inborn_err_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">From <a class="bk_pop" href="#mga3.REF.wortmann.2013a.923">Wortmann et al [2013a]</a>. Click <a href="/books/NBK1473/bin/mga3-Table3a.pdf">here</a> (pdf) for an expanded version of the table with information on protein subcellular localization and function.</p></div></dd><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; DCMA = dilated cardiomyopathy with ataxia; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; NOS= not otherwise specified; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd><dt>1. </dt><dd><div id="mga3.TF.3.1"><p class="no_margin">In addition to 3-MGA-uria</p></div></dd></dl></div></div></div><div id="mga3.T.urinary_excretion_of_3mgc_and_3mg" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Urinary Excretion of 3-MGC and 3-MGA in Inborn Errors of Metabolism with 3-Methylglutaconic Aciduria</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1473/table/mga3.T.urinary_excretion_of_3mgc_and_3mg/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mga3.T.urinary_excretion_of_3mgc_and_3mg_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Urinary Excretion</th></tr><tr><th headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2" id="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">3-MGC and 3-MGA in mmol/mol Creatinine</th><th headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2" id="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-Hydroxyisovaleric Acid<br />(3-HIV)</th></tr></thead><tbody><tr><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-methylglutaconyl-CoA hydratase deficiency</td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">500 to 1000&#x000a0;<sup>1</sup></td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Increased</td></tr><tr><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>TAZ</i> defect (<a href="/books/n/gene/barth/">Barth syndrome</a>)</td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild to moderate&#x000a0;<sup>2</sup></td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr><tr><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>OPA3</i> defect (Costeff syndrome)&#x000a0;<sup>3</sup></td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9-187</td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr><tr><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>DNAJC19</i> defect (DCMA syndrome)</td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderate&#x000a0;<sup>4</sup></td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr><tr><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NOS 3-MGA-uria</td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Elevated to variable degrees</td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal</td></tr><tr><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Normal controls</td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3.2-7</td><td headers="hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_1_2 hd_h_mga3.T.urinary_excretion_of_3mgc_and_3mg_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="mga3.TF.4.1"><p class="no_margin">The urinary excretion of 3-methylglutaric acid (3-MGA) correlates with protein intake, whereas, in most individuals with other types of 3-MGCA the amount of 3-MGC in urine is not dependent on dietary leucine [<a class="bk_pop" href="#mga3.REF.sweetman.2001">Sweetman &#x00026; Williams 2001</a>].</p></div></dd><dt>2. </dt><dd><div id="mga3.TF.4.2"><p class="no_margin">Less than ten times the upper limit of normal</p></div></dd><dt>3. </dt><dd><div id="mga3.TF.4.3"><p class="no_margin">In 39 individuals [<a class="bk_pop" href="#mga3.REF.elpeleg.1994.167">Elpeleg et al 1994</a>]</p></div></dd><dt>4. </dt><dd><div id="mga3.TF.4.4"><p class="no_margin">Five- to tenfold normal [<a class="bk_pop" href="#mga3.REF.davey.2006.385">Davey et al 2006</a>]</p></div></dd></dl></div></div></div><p><b>3-methylglutaconyl-CoA hydratase deficiency.</b> The clinical features include nonspecific speech and language delay without metabolic derangement in some individuals and with hypoglycemia and metabolic acidosis in others (<a class="figpopup" href="/books/NBK1473/table/mga3.T.new_classification_for_inborn_err/?report=objectonly" target="object" rid-figpopup="figmga3Tnewclassificationforinbornerr" rid-ob="figobmga3Tnewclassificationforinbornerr">Table 3</a>). Failure to thrive and psychomotor retardation are common. Microcephaly and progressive neurologic impairment with spastic quadriplegia, seizures, and dystonia have been reported. [<a class="bk_pop" href="#mga3.REF.sweetman.2001">Sweetman &#x00026; Williams 2001</a>, <a class="bk_pop" href="#mga3.REF.ijlst.2002.1463">Ijlst et al 2002</a>, <a class="bk_pop" href="#mga3.REF.illsinger.2004.213">Illsinger et al 2004</a>].</p><p><b><i>TAZ</i> defect</b>
<b>(</b><a href="/books/n/gene/barth/"><b>Barth syndrome</b></a><b>).</b> The clinical features include dilated cardiomyopathy associated with skeletal myopathy, neutropenia, and growth retardation (<a class="figpopup" href="/books/NBK1473/table/mga3.T.new_classification_for_inborn_err/?report=objectonly" target="object" rid-figpopup="figmga3Tnewclassificationforinbornerr" rid-ob="figobmga3Tnewclassificationforinbornerr">Table 3</a>) [<a class="bk_pop" href="#mga3.REF.walsh.1999.251">Walsh et al 1999</a>, <a class="bk_pop" href="#mga3.REF.ijlst.2002.1463">Ijlst et al 2002</a>, <a class="bk_pop" href="#mga3.REF.barth.2004.349">Barth et al 2004</a>]. Dilated cardiomyopathy presents within the first year of life or even prenatally [<a class="bk_pop" href="#mga3.REF.barth.2004.349">Barth et al 2004</a>]. Cognitive development is normal, although an associated learning disorder has been described.</p><p>Moderately decreased plasma cholesterol (mostly of the LDL type) may be another clue for diagnosis of Barth syndrome.</p><p><i>TAZ</i> defect cannot always be distinguished from <i>OPA3</i> defect (Costeff syndrome) by urinary organic acid results alone (<a class="figpopup" href="/books/NBK1473/table/mga3.T.urinary_excretion_of_3mgc_and_3mg/?report=objectonly" target="object" rid-figpopup="figmga3Turinaryexcretionof3mgcand3mg" rid-ob="figobmga3Turinaryexcretionof3mgcand3mg">Table 4</a>).</p><p><b><i>DNAJC19</i> defect (DCMA syndrome).</b> DCMA, seen in the Dariusleut Hutterite population of Canada [<a class="bk_pop" href="#mga3.REF.davey.2006.385">Davey et al 2006</a>] is characterized by severe early-onset dilated cardiomyopathy, growth failure, and cerebellar ataxia. Some may have optic atrophy. The <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a> and the lack of skeletal myopathy and neutropenia distinguish DCMA syndrome from Barth syndrome.</p><p><b>Not otherwise specified 3-MGA-uria type</b> (former <b>3-MGCA 4)</b> includes all other individuals with 3-MGCA with normal 3-methylglutaconyl-CoA hydratase enzyme activity, and no defect in <i>TAZ, SERAC1, OPA3, TMEM70</i>, or <i>DNAJC19</i> [<a class="bk_pop" href="#mga3.REF.sweetman.2001">Sweetman &#x00026; Williams 2001</a>, <a class="bk_pop" href="#mga3.REF.gunayaygun.2005.1">Gunay-Aygun 2005</a>]. Most individuals in this group present early in life with nonspecific neurologic findings including psychomotor retardation and muscle tone abnormalities. Cardiomyopathy is common. Some have microcephaly, hearing loss, and retinitis pigmentosa, optic atrophy and/or cataracts. Some asymptomatic adults and pregnant women have been reported. Two brothers with a neurodegenerative disorder also had a myelodysplastic syndrome [<a class="bk_pop" href="#mga3.REF.arn.2006.62">Arn &#x00026; Funanage 2006</a>, <a class="bk_pop" href="#mga3.REF.haimi.2006.69">Haimi et al 2006</a>]. Persistent and episodic lactic acidosis are common. Some individuals have increased excretion of citric acid cycle intermediates.</p><p><b>Differential diagnosis of the clinical findings of <i>OPA3</i>-related methylglutaconic aciduria (Costeff syndrome)</b></p><p><b>Optic atrophy</b> is seen in a number of syndromes as part of a complex <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. The combination of ataxia and optic atrophy is relatively nonspecific.</p><p>Pathologic pallor of optic atrophy may sometimes be difficult to differentiate from the physiologic optic disc pallor of infancy.</p><p><b>Behr syndrome.</b> The clinical picture of Behr syndrome is most similar to <i>OPA3</i>-related methylglutaconic aciduria [<a class="bk_pop" href="#mga3.REF.copeliovitch.2001.512">Copeliovitch et al 2001</a>]. Behr syndrome is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder of childhood-onset optic atrophy and spinocerebellar degeneration characterized by ataxia, spasticity, intellectual disability, posterior column sensory loss, and peripheral neuropathy (OMIM <a href="http://omim.org/entry/210000" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">210000</a>). Ataxia, an obligatory finding in Behr syndrome, is not seen in approximately half of individuals with <i>OPA3</i>-related methylglutaconic aciduria; conversely, most individuals with Behr syndrome do not manifest extrapyramidal dysfunction, one of the major features of <i>OPA3</i>-related methylglutaconic aciduria. Given that some individuals with <i>OPA3</i>-related methylglutaconic aciduria do not have extrapyramidal dysfunction, it is not possible to distinguish Behr syndrome from <i>OPA3</i>-related methylglutaconic aciduria based on clinical findings alone. At this time, <i>OPA3</i>-related methylglutaconic aciduria is distinguished from Behr syndrome by the presence of elevated excretion of 3-MGC and 3-MGA in urine (<a class="figpopup" href="/books/NBK1473/table/mga3.T.urinary_excretion_of_3mgc_and_3mg/?report=objectonly" target="object" rid-figpopup="figmga3Turinaryexcretionof3mgcand3mg" rid-ob="figobmga3Turinaryexcretionof3mgcand3mg">Table 4</a>). It is possible that these two disorders are actually the same entity. It remains to be determined if individuals with Behr syndrome without elevated 3-MGA and 3-MGC excretion have mutation of <i>OPA3</i>.</p><p><b>Cerebral palsy.</b> As the neurologic symptoms of <i>OPA3</i>-related methylglutaconic aciduria are relatively slow to progress, especially if the optic atrophy is not recognized, the disorder may be misdiagnosed as cerebral palsy [<a class="bk_pop" href="#mga3.REF.straussberg.1998.54">Straussberg et al 1998</a>]. Therefore, cerebral palsy-like symptoms accompanied by optic atrophy and extrapyramidal signs in the absence of systemic acidosis should call for determination of urinary 3-MGC.</p></div><div id="mga3.Management"><h2 id="_mga3_Management_">Management</h2><div id="mga3.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>OPA3</i>-related methylglutaconic aciduria (Costeff syndrome), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Complete ophthalmologic examination</div></li><li class="half_rhythm"><div>Visual evoked potentials</div></li><li class="half_rhythm"><div>Complete neurologic examination</div></li><li class="half_rhythm"><div>Developmental/educational assessment</div></li><li class="half_rhythm"><div>Echocardiogram</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="mga3.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Treatment is supportive.</p><p>A multidisciplinary team including a neurologist, orthopedic surgeon, ophthalmologist, biochemical geneticist, and physical therapist is required for the care of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p><p>Visual impairment, spasticity, and movement disorder should be treated as in the general population.</p></div><div id="mga3.Surveillance"><h3>Surveillance</h3><p>Ophthalmologic, neurologic, and orthopedic evaluations as needed based on individual findings are appropriate.</p></div><div id="mga3.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following should be avoided:</p><ul><li class="half_rhythm"><div>Tobacco and alcohol use</div></li><li class="half_rhythm"><div>Medications known to impair mitochondrial function</div></li></ul></div><div id="mga3.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#mga3.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="mga3.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="mga3.Other"><h3>Other</h3><p>A possible role for coenzyme Q<sub>10</sub> (CoQ<sub>10</sub>) has been hypothesized in the treatment of <i>OPA3</i>-related methylglutaconic aciduria because both 3-methylglutaconate (3-MGC) and CoQ<sub>10</sub> can be produced from DMAPP, an intermediate metabolite in the synthesis of cholesterol [<a class="bk_pop" href="#mga3.REF.costeff.1998.33">Costeff et al 1998</a>]. Therefore, if CoQ<sub>10</sub> production is impaired, more DMAPP would possibly be directed through the mevalonate shunt to 3-methyglutaconyl-CoA production. The findings of significantly lower-than-normal plasma concentrations of CoQ<sub>10</sub> in six individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria, in two individuals with Barth syndrome, and in four individuals with unclassified type 3-MGA-uria support this hypothesis.</p><p>However, administration of CoQ<sub>10</sub> to six individuals with <i>OPA3</i>-related 3-methylglutaconic aciduria showed no clinical benefit or change in the excretion of 3-MGC [<a class="bk_pop" href="#mga3.REF.costeff.1998.33">Costeff et al 1998</a>]. The question of whether initiation of CoQ<sub>10</sub> supplements early in the course of disease would prevent some neurologic damage remains to be answered.</p></div></div><div id="mga3.Genetic_Counseling"><h2 id="_mga3_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="mga3.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>OPA3</i>-related 3-methylglutaconic aciduria is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="mga3.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes and therefore carry one mutated <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Once an at-risk sib is known to be unaffected, the risk of his/her being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> is 2/3.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with <i>OPA3</i>-related 3-methylglutaconic aciduria are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>OPA3</i>.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each sib of the proband's parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="mga3.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p><b>Biochemical genetic testing.</b> Because carriers have normal urinary excretion of 3-methylglutaric acid (3-MGA) and 3-methylglutaconate (3-MGC), <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status cannot be determined using biochemical genetic testing.</p><p><b>Molecular genetic testing.</b> Carrier testing for:</p><ul><li class="half_rhythm"><div>At-risk relatives requires prior identification of the pathogenic variants in the family;</div></li><li class="half_rhythm"><div>Individuals of Iraqi Jewish origin relies on targeted analysis for the <a class="figpopup" href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object" rid-figpopup="figmga3Tselectedopa3variants" rid-ob="figobmga3Tselectedopa3variants">c.143-1G&#x0003e;C</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li></ul></div><div id="mga3.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="mga3.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once the pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p><b>Biochemical genetic testing.</b> Measurement of 3-MGC and 3-MGA in amniotic fluid is not reliable.</p></div></div><div id="mga3.Resources"><h2 id="_mga3_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Costeff Support Group</b></div><div>Sheba Medical Center</div><div>Tel Hashomer 52621</div><div>Israel</div><div><b>Phone:</b> +9723530 5017</div><div><b>Fax:</b> +9723530 2658</div><div><b>Email:</b> roma40@012.net.il</div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="https://ghr.nlm.nih.gov/condition/costeff-syndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Costeff syndrome</a></div></li><li class="half_rhythm"><div><b>Save Babies Through Screening Foundation, Inc.</b></div><div>P. O. Box 42197</div><div>Cincinnati OH 45242</div><div><b>Phone:</b> 888-454-3383</div><div><b>Email:</b> email@savebabies.org</div><div><a href="http://www.savebabies.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.savebabies.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>Organic Acidemia Association</b></div><div><b>Phone:</b> 763-559-1797</div><div><b>Fax:</b> 866-539-4060 (toll-free)</div><div><b>Email:</b> kstagni@oaanews.org; menta@oaanews.org</div><div><a href="http://www.oaanews.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.oaanews.org</a></div></li></ul></div><div id="mga3.Molecular_Genetics"><h2 id="_mga3_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="mga3.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>OPA3-Related 3-Methylglutaconic Aciduria: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1473/table/mga3.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mga3.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_mga3.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_mga3.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_mga3.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_mga3.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_mga3.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_mga3.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_mga3.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/80207" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>OPA3</i></a></td><td headers="hd_b_mga3.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=80207" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19q13<wbr style="display:inline-block"></wbr>​.32</a></td><td headers="hd_b_mga3.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q9H6K4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Optic atrophy 3 protein</a></td><td headers="hd_b_mga3.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://databases.lovd.nl/shared/genes/OPA3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OPA3 @ LOVD</a></td><td headers="hd_b_mga3.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=OPA3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OPA3</a></td><td headers="hd_b_mga3.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=OPA3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OPA3</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="mga3.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="mga3.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for OPA3-Related 3-Methylglutaconic Aciduria (<a href="/omim/258501,606580" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1473/table/mga3.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mga3.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/258501" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">258501</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3-METHYLGLUTACONIC ACIDURIA, TYPE III; MGCA3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606580" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606580</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">OPA3 GENE; OPA3</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>OPA3</i> comprises two exons and spans 32 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1473/#mga3.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> A clinically non-significant <i>OPA3</i> sequence variant, c.231T&#x0003e;C, was found in 60 of 98 control alleles [<a class="bk_pop" href="#mga3.REF.neas.2005.525">Neas et al 2005</a>].</p><p><b>Pathogenic variants</b> (see <a class="figpopup" href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object" rid-figpopup="figmga3Tselectedopa3variants" rid-ob="figobmga3Tselectedopa3variants">Table 5</a>)</p><ul><li class="half_rhythm"><div><b>c.143-1G&#x0003e;C.</b> This <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> acceptor <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant in <i>OPA3</i> is the cause of <i>OPA3</i>-related 3-methylglutaconic aciduria in all individuals of Iraqi Jewish origin tested to date [<a class="bk_pop" href="#mga3.REF.anikster.2001.1218">Anikster et al 2001</a>]. The resulting lack of <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> expression manifests as the absence of an <i>OPA3</i> band on a northern blotting of fibroblasts from <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and as an inability to amplify <i>OPA3</i> using the blood <a class="def" href="/books/n/gene/glossary/def-item/cdna/">cDNA</a> of affected individuals [<a class="bk_pop" href="#mga3.REF.anikster.2001.1218">Anikster et al 2001</a>].</div></li><li class="half_rhythm"><div><b>p.Gly93Ser.</b> A <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> c.277G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/single-nucleotide-variant/">single-nucleotide variant</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 of <i>OPA3</i>, resulting in a p.Gly93Ser substitution, is identified in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> members of a French family with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy and cataract [<a class="bk_pop" href="#mga3.REF.reynier.2004.e110">Reynier et al 2004</a>].</div></li><li class="half_rhythm"><div><b>p.Gln105Glu.</b> A <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> c.313C&#x0003e;G transversion in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2 of <i>OPA3</i>, resulting in a p.Gln105Glu substitution, is identified in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> members of a family with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy and cataract [<a class="bk_pop" href="#mga3.REF.reynier.2004.e110">Reynier et al 2004</a>].</div></li></ul><p>Heterozygous <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> pathogenic variants p.Gly93Ser and p.Gln105Glu result in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#mga3.REF.reynier.2004.e110">Reynier et al 2004</a>].</p><div id="mga3.T.selected_opa3_variants" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Selected <i>OPA3</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1473/table/mga3.T.selected_opa3_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__mga3.T.selected_opa3_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_mga3.T.selected_opa3_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant<br />Classification</th><th id="hd_h_mga3.T.selected_opa3_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_mga3.T.selected_opa3_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_mga3.T.selected_opa3_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.231T&#x0003e;C</td><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(=)&#x000a0;<sup>2</sup></td><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_4" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/156151425" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_025136<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/13376717" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_079412<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.143-1G&#x0003e;C<br />(IVS1-1G&#x0003e;C)</td><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td></tr><tr><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.277G&#x0003e;A</td><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly93Ser&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.313C&#x0003e;G</td><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln105Glu&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.320_337del</td><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln108_Glu113del</td></tr><tr><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.415C&#x0003e;T</td><td headers="hd_h_mga3.T.selected_opa3_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln139Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="mga3.TF.5.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="mga3.TF.5.2"><p class="no_margin">p.(=) designates that protein has not been analyzed, but no change is expected.</p></div></dd><dt>3. </dt><dd><div id="mga3.TF.5.3"><p class="no_margin">Pathogenic variants associated with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> optic atrophy and cataract</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>OPA3</i> encodes a 179-amino acid (20-kd) protein that contains a mitochondrial targeting peptide, NRIKE, at amino acid residues 25-29 and is predicted to be exported to the mitochondrion [<a class="bk_pop" href="#mga3.REF.anikster.2001.1218">Anikster et al 2001</a>]. It is ubiquitously expressed, with highest expression in skeletal muscle and kidney. In the brain, the cerebral cortex, medulla, cerebellum, and frontal lobe have slightly increased expression [<a class="bk_pop" href="#mga3.REF.anikster.2001.1218">Anikster et al 2001</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The impact of the <i>OPA3</i> pathogenic variants on cell function is unknown. Homozygous acceptor <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variant c.143-1G&#x0003e;C in <i>OPA3</i> with loss of function leads to typical <i>OPA3</i>-related methylglutaconic aciduria.</p><p><b>Animal model.</b> An ENU-induced mutant mouse carrying the <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant c.365T&#x0003e;C (p.Leu122Pro) of <i>Opa3</i> showed a normal <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in the <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> state. However, mice <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for this variant display severe multisystem disease including cardiomyopathy, movement disorder, and optic nerve involvement; life span is reduced [<a class="bk_pop" href="#mga3.REF.davies.2008.368">Davies et al 2008</a>].</p></div><div id="mga3.References"><h2 id="_mga3_References_">References</h2><div id="mga3.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.anikster.2001.1218">Anikster Y, Kleta R, Shaag A, Gahl WA, Elpeleg O. Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. <span><span class="ref-journal">Am J Hum Genet. </span>2001;<span class="ref-vol">69</span>:1218–24.</span> [<a href="/pmc/articles/PMC1235533/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1235533</span></a>] [<a href="/pubmed/11668429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11668429</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.arn.2006.62">Arn P, Funanage VL. 3-methylglutaconic aciduria disorders: the clinical spectrum increases. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2006;<span class="ref-vol">28</span>:62–3.</span> [<a href="/pubmed/16462574" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16462574</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.barth.2004.349">Barth PG, Valianpour F, Bowen VM, Lam J, Duran M, Vaz FM, Wanders RJ. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. <span><span class="ref-journal">Am J Med Genet A. </span>2004;<span class="ref-vol">126A</span>:349–54.</span> [<a href="/pubmed/15098233" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15098233</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.copeliovitch.2001.512">Copeliovitch L, Katz K, Arbel N, Harries N, Bar-On E, Soudry M. Musculoskeletal deformities in Behr syndrome. <span><span class="ref-journal">J Pediatr Orthop. </span>2001;<span class="ref-vol">21</span>:512–4.</span> [<a href="/pubmed/11433166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11433166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.costeff.1998.33">Costeff H, Apter N, Elpeleg ON, Prialnic M, Bohles HJ. Ineffectiveness of oral coenzyme Q10 supplementation in 3-methylglutaconic aciduria, type 3. <span><span class="ref-journal">Brain Dev. </span>1998;<span class="ref-vol">20</span>:33–5.</span> [<a href="/pubmed/9533558" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9533558</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.davey.2006.385">Davey KM, Parboosingh JS, McLeod DR, Chan A, Casey R, Ferreira P, Snyder FF, Bridge PJ, Bernier FP. Mutation of DNAJC19, a human homologue of yeast inner mitochondrial membrane co-chaperones, causes DCMA syndrome, a novel autosomal recessive Barth syndrome-like condition. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:385–93.</span> [<a href="/pmc/articles/PMC2564511/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564511</span></a>] [<a href="/pubmed/16055927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16055927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.davies.2008.368">Davies VJ, Powell KA, White KE, Yip W, Hogan V, Hollins AJ, Davies JR, Piechota M, Brownstein DG, Moat SJ, Nichols PP, Wride MA, Boulton ME, Votruba M. A missense mutation in the murine Opa3 gene models human Costeff syndrome. <span><span class="ref-journal">Brain. </span>2008;<span class="ref-vol">131</span>:368–80.</span> [<a href="/pubmed/18222992" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18222992</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.elpeleg.1994.167">Elpeleg ON, Costeff H, Joseph A, Shental Y, Weitz R, Gibson KM. 3-Methylglutaconic aciduria in the Iraqi-Jewish 'optic atrophy plus' (Costeff) syndrome. <span><span class="ref-journal">Dev Med Child Neurol. </span>1994;<span class="ref-vol">36</span>:167–72.</span> [<a href="/pubmed/7510656" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7510656</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.gunayaygun.2005.1">Gunay-Aygun M. 3-Methylglutaconic aciduria: a common biochemical marker in various syndromes with diverse clinical features. <span><span class="ref-journal">Mol Genet Metab. </span>2005;<span class="ref-vol">84</span>:1–3.</span> [<a href="/pubmed/15719488" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15719488</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.haimi.2006.69">Haimi M, Elhasid R, Gershoni-Baruch R, Izraeli S, Wanders RJ, Mandel H. Myeloid dysplasia in familial 3-methylglutaconic aciduria. <span><span class="ref-journal">J Pediatr Hematol Oncol. </span>2006;<span class="ref-vol">28</span>:69–72.</span> [<a href="/pubmed/16462576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16462576</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.ho.2008.s419">Ho G, Walter JH, Christodoulou J. Costeff optic atrophy syndrome: New clinical case and novel molecular findings. <span><span class="ref-journal">J Inherit Metab Dis. </span>2008;<span class="ref-vol">31</span> Suppl 2:S419–23.</span> [<a href="/pubmed/18985435" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18985435</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.ijlst.2002.1463">Ijlst L, Loupatty FJ, Ruiter JP, Duran M, Lehnert W, Wanders RJ. 3-Methylglutaconic aciduria type I is caused by mutations in AUH. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:1463–6.</span> [<a href="/pmc/articles/PMC378594/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC378594</span></a>] [<a href="/pubmed/12434311" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12434311</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.illsinger.2004.213">Illsinger S, Lucke T, Zschocke J, Gibson KM, Das AM. 3-methylglutaconic aciduria type I in a boy with fever-associated seizures. <span><span class="ref-journal">Pediatr Neurol. </span>2004;<span class="ref-vol">30</span>:213–5.</span> [<a href="/pubmed/15033206" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15033206</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.kleta.2002.201">Kleta R, Skovby F, Christensen E, Rosenberg T, Gahl WA, Anikster Y. 3-Methylglutaconic aciduria type III in a non-Iraqi-Jewish kindred: clinical and molecular findings. <span><span class="ref-journal">Mol Genet Metab. </span>2002;<span class="ref-vol">76</span>:201–6.</span> [<a href="/pubmed/12126933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12126933</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.neas.2005.525">Neas K, Bennetts B, Carpenter K, White R, Kirk EP, Wilson M, Kelley R, Baric I, Christodoulou J. OPA3 mutation screening in patients with unexplained 3-methylglutaconic aciduria. <span><span class="ref-journal">J Inherit Metab Dis. </span>2005;<span class="ref-vol">28</span>:525–32.</span> [<a href="/pubmed/15902555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15902555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.reynier.2004.e110">Reynier P, Amati-Bonneau P, Verny C, Olichon A, Simard G, Guichet A, Bonnemains C, Malecaze F, Malinge MC, Pelletier JB, Calvas P, Dollfus H, Belenguer P, Malthiery Y, Lenaers G, Bonneau D. OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:e110.</span> [<a href="/pmc/articles/PMC1735897/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735897</span></a>] [<a href="/pubmed/15342707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15342707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.straussberg.1998.54">Straussberg R, Brand N, Gadoth N. 3-Methyl glutaconic aciduria in Iraqi Jewish children may be misdiagnosed as cerebral palsy. <span><span class="ref-journal">Neuropediatrics. </span>1998;<span class="ref-vol">29</span>:54–6.</span> [<a href="/pubmed/9553953" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9553953</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.sweetman.2001">Sweetman L, Williams JC. Branched chain organic acidurias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. <em>The Metabolic and Molecular Basis of Inherited Disease.</em> Vol 2. New York, NY: McGraw-Hill; 2001:2137-40.</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.walsh.1999.251">Walsh R, Conway H, Roche G, Mayne PD. What is the origin of 3-methylglutaconic acid? <span><span class="ref-journal">J Inherit Metab Dis. </span>1999;<span class="ref-vol">22</span>:251–5.</span> [<a href="/pubmed/10384380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10384380</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.wortmann.2013a.923">Wortmann SB, Duran M, Anikster Y, Barth PG, Sperl W, Zschocke J, Morava E, Wevers RA. Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013a;<span class="ref-vol">36</span>:923–8.</span> [<a href="/pubmed/23296368" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23296368</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="mga3.REF.wortmann.2013b.913">Wortmann SB, Kluijtmans LA, Rodenburg RJ, Sass JO, Nouws J, van Kaauwen EP, Kleefstra T, Tranebjaerg L, de Vries MC, Isohanni P, Walter K, Alkuraya FS, Smuts I, Reinecke CJ, van der Westhuizen FH, Thorburn D, Smeitink JA, Morava E, Wevers RA. 3-Methylglutaconic aciduria-lessons from 50 genes and 977 patients. <span><span class="ref-journal">J Inherit Metab Dis. </span>2013b;<span class="ref-vol">36</span>:913–21.</span> [<a href="/pubmed/23355087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23355087</span></a>]</div></li></ul></div></div><div id="mga3.Chapter_Notes"><h2 id="_mga3_Chapter_Notes_">Chapter Notes</h2><p><b>Author History</b></p><p>Yair Anikster, MD, PhD (2006-present)<br />William A Gahl, MD, PhD; National Institutes of Health (2006-2013)<br />Meral Gunay-Aygun, MD (2006-present)<br />Marian Huizing, PhD (2013-present)</p><div id="mga3.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>19 December 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>31 March 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>28 July 2006 (me) Review posted live</div></li><li class="half_rhythm"><div>27 April 2006 (mga) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1473</span><span class="label">PMID: <a href="/pubmed/20301646" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301646</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/leigh-nucl-ov/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/dfnb9/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1473&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1473/?report=reader">PubReader</a></li><li><a href="/books/NBK1473/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1473" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1473" style="display:none" title="Cite this Page"><div class="bk_tt">Gunay-Aygun M, Huizing M, Anikster Y. OPA3-Related 3-Methylglutaconic Aciduria. 2006 Jul 28 [Updated 2013 Dec 19]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1473/pdf/Bookshelf_NBK1473.pdf">PDF version of this page</a> (462K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#mga3.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#mga3.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#mga3.Clinical_Characeristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characeristics</a></li><li><a href="#mga3.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#mga3.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#mga3.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#mga3.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#mga3.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#mga3.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#mga3.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#mga3.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=80207[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">OPA3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1473+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1474142" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1474142" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1474142" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1474142" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24749080" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Two novel compound heterozygous mutations in &lt;i&gt;OPA3&lt;/i&gt; in two siblings with OPA3-related 3-methylglutaconic aciduria.</a><span class="source">[Mol Genet Metab Rep. 2014]</span><div class="brieflinkpop offscreen_noflow">Two novel compound heterozygous mutations in &lt;i&gt;OPA3&lt;/i&gt; in two siblings with OPA3-related 3-methylglutaconic aciduria.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lam C, Gallo LK, Dineen R, Ciccone C, Dorward H, Hoganson GE, Wolfe L, Gahl WA, Huizing M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Mol Genet Metab Rep. 2014 Jan 1; 1:114-123. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18985435" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Costeff optic atrophy syndrome: new clinical case and novel molecular findings.</a><span class="source">[J Inherit Metab Dis. 2008]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Costeff optic atrophy syndrome: new clinical case and novel molecular findings.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ho G, Walter JH, Christodoulou J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Inherit Metab Dis. 2008 Dec; 31 Suppl 2:S419-23. Epub 2008 Nov 7.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11668429" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews.</a><span class="source">[Am J Hum Genet. 2001]</span><div class="brieflinkpop offscreen_noflow">Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Anikster Y, Kleta R, Shaag A, Gahl WA, Elpeleg O. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Hum Genet. 2001 Dec; 69(6):1218-24. Epub 2001 Oct 19.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20627962" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">A model of Costeff Syndrome reveals metabolic and protective functions of mitochondrial OPA3.</a><span class="source">[Development. 2010]</span><div class="brieflinkpop offscreen_noflow">A model of Costeff Syndrome reveals metabolic and protective functions of mitochondrial OPA3.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pei W, Kratz LE, Bernardini I, Sood R, Yokogawa T, Dorward H, Ciccone C, Kelley RI, Anikster Y, Burgess HA, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Development. 2010 Aug 1; 137(15):2587-96. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24741715" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> MEGDEL Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> MEGDEL Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wortmann SB, de Brouwer APM, Wevers RA, Morava E. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301646" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301646" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040dbfdde089116957ea13">OPA3-Related 3-Methylglutaconic Aciduria - GeneReviews®</a><div class="ralinkpop offscreen_noflow">OPA3-Related 3-Methylglutaconic Aciduria - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:32:47-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE885619E03EEB71000000000B1003AC&amp;ncbi_session=CE885619E040DBE1_2832SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1473%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1473&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1473/&amp;ncbi_pagename=OPA3-Related 3-Methylglutaconic Aciduria - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE885619E040DBE1_2832SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>